Human microdosing for the prediction of patient response

Bioanalysis

Volumn 2, Issue 3, 2010, Pages 373-376

  Henderson, Paul T ^a   Pan, Chong Xian ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; CARBON 14; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; OXALIPLATIN; PLATINUM COMPLEX; DRUG;

DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG INDUSTRY; DRUG MICRODOSE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RADIATION DOSE; RADIATION EXPOSURE; RADIOACTIVITY; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; DRUG DEVELOPMENT; EDITORIAL; METHODOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC);

CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS;

EID: 78649237052     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.3     Document Type: Review

References (26)

1. Brown K, Dingley KH, Turteltaub KW. Accelerator mass spectrometry for biomedical research. Methods Enzymol. 402, 423-443 (2005). (Pubitemid 43053135)
2. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4(8), 1021-1033 (2008).
3. Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW, Henderson PT. Measurement of 7,8-dihydro-8-oxo-2′- deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc. Natl Acad. Sci USA 104(27), 11203-11208 (2007). (Pubitemid 47175119)
4. Zhou X, Liberman RG, Skipper PL, Margolin Y, Tannenbaum SR, Dedon PC. Quantification of DNA strand breaks and abasic sites by oxime derivatization and accelerator mass spectrometry: application to gamma-radiation and peroxynitrite. Anal. Biochem. 343(1), 84-92 (2005). (Pubitemid 40978612)
5. Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR. Characterization of testosterone 11b-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab. Dispos. 33(6), 714-718 (2005). (Pubitemid 40686622)
6. Hillier SM, Marquis JC, Zayas B et al. DNA adducts formed by a novel antitumor agent 11b-dichloro in vitro and in vivo. Mol. Cancer Ther. 5(4), 977-984 (2006). (Pubitemid 43724598)
7. Watanabe K, Liberman RG, Skipper PL, Tannenbaum SR, Guengerich FP. Analysis of DNA adducts formed in vivo in rats and mice from 1,2-dibromoethane, 1,2-dichloroethane, dibromomethane, and dichloromethane using HPLC/accelerator mass spectrometry and relevance to risk estimates. Chem. Res. Toxicol. 20(11), 1594-1600 (2007). (Pubitemid 350275604)
8. Tompkins EM, Farmer PB, Lamb JH et al. A novel 14C-postlabeling assay using accelerator mass spectrometry for the detection of O6-methyldeoxy- guanosine adducts. Rapid Commun. Mass Spectrom. 20(5), 883-891 (2006). (Pubitemid 43326698)
9. Marsden DA, Jones DJ, Britton RG et al. Dose-response relationships for N7-(2- hydroxyethyl)guanine induced by low-dose [14C]ethylene oxide: evidence for a novel mechanism of endogenous adduct formation. Cancer Res. 69(7), 3052-3059 (2009).
10. Jubert C, Mata J, Bench G et al. Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B1 pharmacokinetics in human volunteers. Cancer Prev. Res. 2(12), 1015-1022 (2009).
11. Dingley KH, Roberts ML, Velsko CA, Turteltaub KW. Attomole detection of 3H in biological samples using accelerator mass spectrometry: application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry. Chem. Res. Toxicol. 11(10), 1217-1222 (1998). (Pubitemid 28500803)
12. Fitzgerald RL, Hillegonds DJ, Burton DW et al. 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. Clin. Chem. 51(11), 2095-2102 (2005). (Pubitemid 41532625)
13. Denk E, Hillegonds D, Hurrell RF et al. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. J. Bone Miner. Res. 22(10), 1518-1525 (2007). (Pubitemid 351229322)
14. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4(8), 1021-1033 (2008).
15. Ings RM. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1(7), 1293-1305 (2009).
16. Sandhu P, Vogel JS, Rose MJ et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. 32(11), 1254-1259 (2004). (Pubitemid 39410909)
17. Carkeet C, Dueker SR, Lango J et al. Human vitamin B12 absorption measurement by accelerator mass spectrometry using specifically labeled (14) C-cobalamin. Proc. Natl Acad. Sci. USA 103(15), 5694-5699 (2006).
18. Hah SS, Stivers KM, de Vere White R, Henderson PT. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem. Res. Toxicol. 19(5), 622-626 (2006). (Pubitemid 43800978)
19. Hah SS, Sumbad RA, de Vere White R, Turteltaub KW, Henderson PT. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem. Res. Toxicol. 20(12), 1745-1751 (2007).
20. Liberman RG, Tannenbaum SR, Hughey BJ et al. An interface for direct analysis of 14C in nonvolatile samples by accelerator mass spectrometry. Anal. Chem. 76(2), 328-334 (2004). (Pubitemid 38090768)
21. Prakash C, Shaffer CL, Tremaine LM et al. Application of liquid chromatography- accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 1(3), 226-231 (2007).
22. Flarakos J, Liberman RG, Tannenbaum SR, Skipper PL. Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal. Chem. 80(13), 5079-5085 (2008). (Pubitemid 351956318)
23. Simon GR, Begum M, Bepler G. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol. 4(1), 51-59 (2008). (Pubitemid 351372606)
24. European Union Microdose AMS Partnership Programme www.eumapp.com
25. Vitalea Biosciences Incorporated www.vitaleascience.com
26. Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory https://cams.llnl.gov